Antiviral drugs of Gilead Sciences Pharmaceutical Company are licensed for emergency use by Covid-19 patients by the US government.
According to Bloomberg, US President Donald Trump said the Food and Drug Administration (FDA) has granted an emergency use for Gildes Sciences’ Remdesivir.
As such, this product is used without adequate safety and efficacy data. According to the results of a clinical study, Remdesivir can shorten the recovery time of Covid-19 patients.
“Licensing takes place at the speed of light. The time from clinical trials to licensing is only 90 days,” Bloomberg quoted FDA Commissioner Stephen Hahn as saying.
According to the FDA, emergency use is limited to Covid-19 patients with low blood oxygen levels or need respiratory support. A study conducted by the US this week showed that patients treated with Remdesivir recovered after 11 days, while others needed 15 days.
According to Bloomberg, finding a reliable cure is very important to reopening the US economy. Remdesivir can help control corona virus and create a bridge to future vaccines.
Gilead pledged to donate 1.5 million doses of Remdesivir, the entire current supply of the company. That’s enough for 140,000 patients with a 10-day treatment period.
“Because of the limited supply and the dependence on the severity of the patient, hospitals with intensive care units and hospitals most in need of medicine will be given priority in the distribution of Remdesivir,” Gilead said. Father.
The drug will be manufactured by Gilead and distributed by the US government. Hospitalized patients who require oxygen support account for about 14% of Covid-19 patients, according to initial studies. Patients on ventilators or pacemakers must be treated for 10 days, while others should be on medication for 5 days, according to Gilead.
Gilead is now urgently increasing production scale of Remdesivir by partnering with partners around the world.